Skip to content
Screener

D&A at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$102M-4.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.96B+0.8%
Staar Surgical logo
Staar SurgicalSTAA
$2.11M-9.8%
Apyx Medical Corporation logo
Apyx Medical CorporationAPYX
$202K+46.4%
Ardelyx logo
ArdelyxARDX
$604K-4.3%
Ironwood Pharmaceuticals logo
Ironwood PharmaceuticalsIRWD
$457K-2.1%

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$2.37B+11.7%
Enterprise value$21.83B-1.3%
P/S0.2×0.0×

Profitability

See full
Gross margin71.4%
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%
Debt / equity45.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The source filing: Bausch Health Companies’s 10-Q, filed April 30, 2026.

Filed
Apr 29, 2026, 6:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885590-26-000053
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Cash Flows From Operating Activities
Net loss$(1,431)$(86)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization of intangible assets295305
Amortization and write-off of debt premiums, discounts and issuance costs1415
Goodwill impairments1,426
Acquisition-related contingent consideration12(11)
Allowances for losses on trade receivable and inventories2626

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Bausch Health Companies's D&A?
Bausch Health Companies (BHC) reported D&A of $295M in Q1 2026.
How has Bausch Health Companies's D&A changed year-over-year?
Bausch Health Companies's D&A decreased by 3.3% year-over-year, from $305M to $295M.
What is the long-term trend for Bausch Health Companies's D&A?
Over 4 years (2021 to 2025), Bausch Health Companies's D&A has grown at a -6.1% compound annual growth rate (CAGR), from $1.55B to $1.21B.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about Bausch Health Companies's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude